Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer

KRAS is an important tumor intrinsic factor driving immune suppression in colorectal cancer (CRC). In this study, we demonstrate that SLC25A22 underlies mutant KRAS-induced immune suppression in CRC. In immunocompetent male mice and humanized male mice models, SLC25A22 knockout inhibits KRAS-mutant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qiming, Peng, Yao, Ji, Fenfen, Chen, Huarong, Kang, Wei, Chan, Lam-Shing, Gou, Hongyan, Lin, Yufeng, Huang, Pingmei, Chen, Danyu, Wei, Qinyao, Su, Hao, Liang, Cong, Zhang, Xiang, Yu, Jun, Wong, Chi Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403583/
https://www.ncbi.nlm.nih.gov/pubmed/37542037
http://dx.doi.org/10.1038/s41467-023-39571-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403583/
https://www.ncbi.nlm.nih.gov/pubmed/37542037
http://dx.doi.org/10.1038/s41467-023-39571-6

Ejemplares similares